menu

CME: REDUCE-IT Trial Studying Icosapent Ethyl: An In-Depth Review of USA Dataset with Commentary

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

REDUCE-IT Trial Studying Icosapent Ethyl: An In-Depth Review of USA Dataset with Commentary

close
0.50 credits
30 minutes
REDUCE-IT Trial Studying Icosapent Ethyl: An In-Depth Review of USA Dataset with Commentary
Restart
Resume
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Related
Comments
  • Overview

    Join an internationally recognized panel of experts as they provide a comprehensive review and commentary of the results from the REDUCE-IT trial, which studied the effect of icosapent ethyl on cardiovascular outcomes. The expert panel also offers insights and pearls on how these results affect clinical lipid management in patients at risk for ASCVD, especially after the FDA expanded the indication of icosapent ethyl to include the reduction of ASCVD events.

    Time

    Topic

    Format

    16 minutes

    REDUCE-IT USA Subgroup Analysis
    Deepak L. Bhatt, MD

    Audio over slides

      7 minutes

    Panel Discussion 1 and Q&A

    Audio

      8 minutes

    Panel Discussion 2

    Video

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Roger Blumenthal, MD (Co-Chair)
    Director, Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease
    Professor of Medicine
    The Johns Hopkins School of Medicine
    Baltimore, MD
    No relationship reported.

    Peter Libby, MD (Co-Chair)
    Cardiovascular Specialist Brigham and Women’s Hospital
    Mallinckrodt Professor of Medicine Harvard Medical School
    Boston, MA
    Scientific Advisory Board Member: Amgen, Corvidia Therapeutics, DalCor Pharmaceuticals, IFM Therapeutics, Kowa Pharmaceuticals, Olatec Therapeutics, Medimmune, Novartis, XBiotech, Inc.
    Contracted Research: Novartis

    P. Gabriel Steg, MD
    Professor, Cardiology Department
    Paris Diderot University
    Director, Coronary Care Unit
    Hospital Bichat-Claude Bernard
    Paris, France
    Contracted Research: Amarin, Bayer, Sanofi, and Servier
    Scientific Advisory Board Member : Amarin, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Pfizer, Sanofi, Servier
    Consulting Fees: Amgen, Novo-Nordisk, Regeneron

    R. Preston Mason, PhD
    Lecturer on Medicine, Cardiovascular Division Brigham & Women’s Hospital
    Harvard Medical School
    Scientific Director and Co-Founder
    Elucida Research, LLC
    Boston, MA
    Consulting Fees: Amarin, Pfizer
    Contracted Research: ARCA, Amarin, Amgen, Pfizer, Novartis

    Deepak L. Bhatt, MD
    Executive Director of Interventional Cardiovascular Programs
    Brigham and Women’s Hospital Heart & Vascular Center Professor of Medicine
    Harvard Medical School
    Boston, MA
    Contracted Research: Abbott, Amarin, Amgen, AstraZeneca, Bayer, Boehringer lngelheim, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, ldorsia, Ironwood, lschemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company

    Robert H. Eckel, MD
    Professor of Medicine, Emeritus
    Division of Endocrinology, Metabolism, and Diabetes Division of Cardiology
    University of Colorado Anschutz Medical Campus
    Aurora, CO
    Consulting Fees: Novo Nordisk, Sanofi
    Contracted Research: ENDECE, LLC

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss the recent cardiovascular outcomes trials results and their clinical implications in reducing ASCVD adverse events
    • Recognize the importance of managing total cardiovascular disease risk beyond lowering LDL-C
    • Apply evidence-based guidelines and recent randomized clinical trial evidence to reduce residual ASCVD risk
  • Target Audience

    This activity is intended for cardiovascular healthcare professionals including physicians, nurses, and pharmacists who manage patients or work in a health system with relevant issues/challenges in the management of these patients.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Join an internationally recognized panel of experts as they provide a comprehensive review and commentary of the results from the REDUCE-IT trial, which studied the effect of icosapent ethyl on cardiovascular outcomes. The expert panel also offers insights and pearls on how these results affect clinical lipid management in patients at risk for ASCVD, especially after the FDA expanded the indication of icosapent ethyl to include the reduction of ASCVD events.

    Time

    Topic

    Format

    16 minutes

    REDUCE-IT USA Subgroup Analysis
    Deepak L. Bhatt, MD

    Audio over slides

      7 minutes

    Panel Discussion 1 and Q&A

    Audio

      8 minutes

    Panel Discussion 2

    Video

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Roger Blumenthal, MD (Co-Chair)
    Director, Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease
    Professor of Medicine
    The Johns Hopkins School of Medicine
    Baltimore, MD
    No relationship reported.

    Peter Libby, MD (Co-Chair)
    Cardiovascular Specialist Brigham and Women’s Hospital
    Mallinckrodt Professor of Medicine Harvard Medical School
    Boston, MA
    Scientific Advisory Board Member: Amgen, Corvidia Therapeutics, DalCor Pharmaceuticals, IFM Therapeutics, Kowa Pharmaceuticals, Olatec Therapeutics, Medimmune, Novartis, XBiotech, Inc.
    Contracted Research: Novartis

    P. Gabriel Steg, MD
    Professor, Cardiology Department
    Paris Diderot University
    Director, Coronary Care Unit
    Hospital Bichat-Claude Bernard
    Paris, France
    Contracted Research: Amarin, Bayer, Sanofi, and Servier
    Scientific Advisory Board Member : Amarin, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Pfizer, Sanofi, Servier
    Consulting Fees: Amgen, Novo-Nordisk, Regeneron

    R. Preston Mason, PhD
    Lecturer on Medicine, Cardiovascular Division Brigham & Women’s Hospital
    Harvard Medical School
    Scientific Director and Co-Founder
    Elucida Research, LLC
    Boston, MA
    Consulting Fees: Amarin, Pfizer
    Contracted Research: ARCA, Amarin, Amgen, Pfizer, Novartis

    Deepak L. Bhatt, MD
    Executive Director of Interventional Cardiovascular Programs
    Brigham and Women’s Hospital Heart & Vascular Center Professor of Medicine
    Harvard Medical School
    Boston, MA
    Contracted Research: Abbott, Amarin, Amgen, AstraZeneca, Bayer, Boehringer lngelheim, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, ldorsia, Ironwood, lschemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company

    Robert H. Eckel, MD
    Professor of Medicine, Emeritus
    Division of Endocrinology, Metabolism, and Diabetes Division of Cardiology
    University of Colorado Anschutz Medical Campus
    Aurora, CO
    Consulting Fees: Novo Nordisk, Sanofi
    Contracted Research: ENDECE, LLC

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss the recent cardiovascular outcomes trials results and their clinical implications in reducing ASCVD adverse events
    • Recognize the importance of managing total cardiovascular disease risk beyond lowering LDL-C
    • Apply evidence-based guidelines and recent randomized clinical trial evidence to reduce residual ASCVD risk
  • Target Audience

    This activity is intended for cardiovascular healthcare professionals including physicians, nurses, and pharmacists who manage patients or work in a health system with relevant issues/challenges in the management of these patients.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 4/7/20